[HTML][HTML] PSMA-targeting imaging and theranostic agents—Current status and future perspective
In the past two decades, extensive efforts have been made to develop agents targeting
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …
[HTML][HTML] Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
Y Liu, J Wang, X Hu, Z Pan, T Xu, J Xu, L Jiang… - Drug Resistance …, 2023 - Elsevier
Thyroid cancer is the most prevalent endocrine tumor and its incidence is fast-growing
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …
worldwide in recent years. Differentiated thyroid cancer (DTC) is the most common …
Production, purification and availability of 211At: Near term steps towards global access
Y Feng, MR Zalutsky - Nuclear medicine and biology, 2021 - Elsevier
The promising characteristics of the 7.2-h radiohalogen 211 At have long been recognized;
including having chemical properties suitable for labeling targeting vectors ranging from …
including having chemical properties suitable for labeling targeting vectors ranging from …
[HTML][HTML] Radiolabeled PSMA inhibitors
Simple Summary Prostate cancer remains one of the leading causes of cancer death in men
worldwide. Despite the recent success in the development and clinical application of …
worldwide. Despite the recent success in the development and clinical application of …
Preclinical development in radiopharmaceutical therapy for prostate cancer
Prostate cancer is a leading cause of cancer death in men worldwide. Among the various
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …
[HTML][HTML] PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives
M El Fakiri, NM Geis, N Ayada, M Eder, AC Eder - Cancers, 2021 - mdpi.com
Simple Summary One of the most frequently diagnosed cancer in men is adenocarcinoma of
the prostate. Once the disease is metastatic, only very limited treatment options are …
the prostate. Once the disease is metastatic, only very limited treatment options are …
Recent progress of astatine-211 in endoradiotherapy: Great advances from fundamental properties to targeted radiopharmaceuticals
F Li, Y Yang, J Liao, N Liu - Chinese Chemical Letters, 2022 - Elsevier
Abstract Astatine-211 (211 At, t 1/2= 7.21 h) emitting two α particles with energies of 5.87
and 7.45 MeV, can lead to a high linear energy transfer (LET= 98.84 keV/µm) and short …
and 7.45 MeV, can lead to a high linear energy transfer (LET= 98.84 keV/µm) and short …
[HTML][HTML] PSMA theranostics: science and practice
Simple Summary A significant number of prostate cancer patients will progress to metastatic
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …
Effective treatment of human breast carcinoma xenografts with single-dose 211At-labeled anti-HER2 single-domain antibody fragment
Y Feng, R Meshaw, XG Zhao, S Jannetti… - Journal of Nuclear …, 2023 - Soc Nuclear Med
Single-domain antibody fragments (sdAbs) are attractive for targeted α-particle therapy,
particularly with 211At, because of their rapid accumulation in tumor and clearance from …
particularly with 211At, because of their rapid accumulation in tumor and clearance from …
[HTML][HTML] Emerging role of nuclear medicine in prostate cancer: current state and future perspectives
Simple Summary The huge armamentarium of currently available theragnostic modalities
allows a novel approach to prostate cancer from imaging to therapy. Clinical examination is …
allows a novel approach to prostate cancer from imaging to therapy. Clinical examination is …